Monday, May 17, 2010
Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committe
media: Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
Keeping the GINA in the bottle: asessing the current need for genetic non-discrimination legislation in Canada - full access
"The background to the adoption of the Genetic Information Nondiscrimination Act (GINA) in the United States has important lessons for Canada, especially in view of the increasing tread toward privatized services within the Canadian public health care system. When the US legislation was finally adopted in May 2008, observers rejoiced that “[a]t last, the United States has a federal law that protects consumers from discrimination by health insurers and employers on the basis of genetic information.”1 GINA is the culmination of a long process that began in 1995 when federal lawmakers first introduced the legislation. In the interim, more than 45 American states had passed their own genetic nondiscrimination laws.2
Such a high level of legislative activity indicates a deep and abiding public concern about the issue of genetic discrimination. Yet the same level of angst has yet to make its way north. Although a recent Canadian study reports on perceptions of genetic discrimination with regard to people at risk for Huntington’s disease,3 discussion of the general issue in Canada has been limited and is focused primarily on discrimination in the context of life insurance.4 More significantly, there is no legislation comparable to GINA at either the federal or the provincial/territorial level in Canada. Does the absence of such legislation mean that Canadians are at higher risk of genetic discrimination than Americans? Does Canada require similar legislation?"
Search of: ovarian cancer | Open Studies | received from 04/01/2010 to 05/17/2010 - List Results - ClinicalTrials.gov
Found 25 studies with search of: ovarian cancer - Open Studies - received from 04/01/2010 to 05/17/2010
amednews: Hospitals exchange of cost data clears antitrust hurdle :: May 17, 2010 ... American Medical News
"Quality-adjusted pricing also should be taken into account, he said. "From an antitrust perspective, when dealing with a service industry ... just looking at cost may say very little."
add your opinions cancer oncology alternatives complimentary medicine Canada U.S. , costs , hospitals
amednews: Informed consent: Hospitals explore personalizing risks :: May 17, 2010 ... American Medical News
"It is well-known from the medical literature that informed consent is neither informed nor consensual," said John Spertus, MD, MPH"
"The (web)site (now closed down)claimed the powder was the experimental cancer drug sodium dichloroacetate (DCA)